Legal
DOJ Signals Expanded Health Care Fraud, Corporate Crime Crackdown
At the STAT Summit, Department of Justice officials said they are expanding investigations into corporate wrongdoing in health care while continuing to pursue Medicare and Medicaid fraud, warning executives against conduct comparable to the Theranos case. The announcement signals heightened federal scrutiny of health care companies' corporate governance and compliance practices, not just billing fraud. No specific new cases, rules, or timelines were detailed in the report. The comments reflect a continuation and expansion of the Trump administration's existing anti-fraud enforcement posture into broader corporate accountability.
Why it mattersHealth care executives and compliance officers should expect increased DOJ scrutiny of corporate conduct, not just claims-level fraud, raising personal and organizational liability exposure for Medicaid-related billing and governance practices.